agent marked an advance into a new therapeutic era. Now that adrenal substitution therapy is a practical measure, adrenalectomy for a variety of disorders has become increasingly popular. Total or subtotal adrenalectomy is now orthodox therapy for Cushing's syndrome, and total adrenalectomy has also been extensively used in the treatment of metastatic malignant disease and of malignant hypertension; it has also been empirically performed in the treatment of a number of disorders: diabetes mellitus, schizophrenia, and rheumatoid arthritis, to mention three. Substitution therapy has therefore become a day-to-day problem in the wards of many hospitals, and, as a natural sequence, the treatment of adrenocortical crisis has become more common than it used to be.
The tempo of practical therapeutics is now so rapid that by the time a new effective form of treatment is evolved and applied in medicine its probable successors are already on the scene, as yet incompletely studied and unproved clinically. This is particularly so in the adrenal-deficiency states, where steroid chases steroid across a constantly changing scene. We have passed from the time of high-salt treatment, through the cortical extract era, from the deoxycortone to the cortisone age, and are now in the happy position of having many practical tools, all of proved efficiency. In spite of this, many patients with adrenal deficiency still lag behind somewhere on this therapeutic pathway; to-day brown lethargic Addisonian patients, on deoxycortone alone, resemble the partially treated patients of the pre-1949 era. Such patients are by no mreans rare even at the time of writing.
The clinical material which forms the basis of this study consists of 150 patients, 5 adrenalectomized for malignant hypertension, 2 for Cushing's syndrome, and 143 for metastatic malignant disease. Details of these cases have been published by Sir Stanford Cade (1954 . Of the metastatic cases, 65 have survived and have been followed-up for more than six months to September, 1956 . The number of " survival years " of these 65 cases now totals 85.3. The two patients with Cushing's syndrome are in good health, four and one year after operation. Of the patients with malignant hypertension only one survives after two years; the others lived 10, 12, 19, and 12 months after operation.
The details of these five patients, all under the care of Dr. Swithin Meadows, have been reported by Van T'Hoff (1956) .
Sodium Loss, Cortisone Deficiency, and Water Intoxication The classical symptoms of adrenal deficiency are increasing weakness, lassitude, and inability to respond to any form of stress, followed by vomiting, diarrhoea. prostration, and finally coma. The blood urea rises as the serum sodium falls; the serum potassium rises steadily as the patient becomes depleted of salt and water. These symptoms are, however, found only typically in a minority of patients; in most cases the early signs and symptoms are more subtle and less easy to define.
In the adrenal-deficient subject, particularly in the adrenalectomized subject suffering from metastatic malignant disease, the variables with which the clinician has to contend daily are: (1) the salt-and-water balance; (2) the cortisone requirements ; and (3) the activity of the underlying (malignant) disease process.
The clinical and biochemical picture may change rap.idly overnight in these severely ill patients. The clinical picture in water intoxication may be very similar to that seen in hyponatraemia, the essential difference being that all blood constituents are diluted in water intoxication and oedema appears with increasing gain in body weight. The appearance of the patient is usually relatively normal in water intoxication (Wynn, 1956) , while the sodium-depleted patient is haggard, with inelastic skin. The two conditions may not, however, be easy to differentiate, and hyponatraemia and waterloading may coexist. Cortisone in this water-intoxication syndrome in adrenalectomized subjects may act as a diuretic agent, and while fluid intake is reduced produces brisk diuresis. It is of interest that Pearson et al. (1953) found that as a result of experimental withdrawal of cortisone in adrenalectomized patients water intoxication occurred and was, in their opinion, an important feature of adrenal insufficiency. The danger of fluid overloading is a real one in such patients; Hollander et al. (1952) (Bartter, 1956) . It is a naturally occurring substance, and was isolated in 1952 from the active amorphous fraction of the adrenal cortex (Simpson and Tait, 1952) . It has been found both in adrenal venous blood and in peripheral blood, in the urine, and in adrenal cortical adenomata. Its effect on renal sodium and potassium excretion is some 30 times that of deoxycortone. It is the most potent sodiumretaining potassium-eliminating hormone yet found in cortical extract, blood, or urine (Luetscher and Curtis, 1955) .
In adrenalectomized man, however, Maclean et al. (1955) In a search for analogues of cortisone and hydrocortisone 9a-fluorohydrocortisone and 9a-chlorohydrocortisone were found to be far more potent salt-retaining agents than hydrocortisone itself. It was later found that in steroids possessing an 11-1 hydroxyl group (hydrocortisone and 9a-fluorohydrocortisone) the addition of the 2-methyl group greatly enhanced sodium-retaining and potassiumlosing activity; a most potent member of this series, 2-methyl-9a-fluorohydrocortisone is said to be 90 times as potent as deoxycortone and three times as powerful as aldosterone (Bymes et al., 1956; Liddle et al., 1956 is to give such patients three sets of tablets. They are instructed to take cortisone 25 mg. twice a day, and if mild symptoms of salt deficiency occur to take a fluorohydrocortisone-cum-cortisone tablet in place of a cortisone tablet every day, every other day, or every three to four days, depending on their symptoms. If, on the other hand, acute deficiency symptoms occur they are instructed to take a 1-mg. tablet of 9a-fluorohydrocortisone for a few doses until symptoms are controlled. With this "three-tablet" scheme many patients are able to avoid the acute crises which previously took them to hospital, and only if vomiting makes oral therapy impossible or an acute crisis occurs in spite of the above treatment are other measures such as intravenous hydrocortisone needed. 9a-fluorohydrocortisone, though not yet generally available, is an extremely useful additional substance in the treatment of those adrenalectomized subjects in whom cortisone given alone does not prevent the development of a negative sodium balance.
Liquorice Root and its Extracts
There is considerable evidence that liquorice and some of its extracts have, given orally, a deoxycortone-like action. Molhuysen et al. (1950) found that water, sodium, and chloride retention occurred with increase in weight and rise in blood pressure and an increase in potassium urinary excretion. Card et al. (1953) confirmed these effects on normal subjects and showed that glycyrrhetinic acid had a similar effect. These workers demonstrated that, unlike deoxycortone, glycyrrhetinic acid did not prolong the survival time of adrenalectomized rats. Groen et al. (1951 Groen et al. ( , 1952 Hudson et al. (1954) found that glycyrrhizin given alone was not enough to maintain three adrenalectomized subjects in health, but that given in conjunction with cortisone the dose of the latter substance could be reduced; on glycyrrhizin alone signs of hypoadrenalism came on gradually after one to two weeks. Mitchell (1956) quotes Hems as failing to find any glucocorticoid action when both glycyrrhizinic acid and glycyrrhetinic acid were tested by the rat-liver glycogen test. The general impression of most workers is that, while having a salt-retaining and water-retaining action these substances have either no glucocorticoid action or insufficient to maintain Addisonian patients in health. Louis and Conn (1956) used ammonium glycyrrhizinate orally in man; in addition to its known action in inducing water, sodium, and chloride retention and producing a mild increase in urinary potassium they found that it consistently decreased excretion of urinary 17-ketosteroids and was capable of inhibiting pituitary release of melanocyte-stimulating hormone-that is, that it was capable of depressing endogenous production of both corticotrophin and M.S.H. in the pituitary. Galal (1955) concluded as a result of animal experiments that glycyrrhetinic acid, given by any route, had an antidiuretic effect rather than a true deoxycortone-like one.
Used in adrenalectomized subjects in conjunction with cortisone, glycyrrhetinic acid has proved in our hands a weak mineralocorticoid, causing some retention of sodium and chloride, but a stronger water-retaining substance. If dosage of glycyrrhetinic acid be raised to 500 mg. daily the cortisone-treated patients will rapidly gain weight and become oedematous; we have twice seen, in our patients, water-loading occurring in the face of persistence of signs of salt deficiency. Galal suggests that this water-loading effect is not mediated through the posterior pituitary, but is probably a direct effect on the renal tubules, stimulating reabsorption of water. The rather variable effects with various preparations of liquorice may well be because of batch variations, for many of these preparations are as yet far from being pure substances.
Addison's Disease The reason for many of the failures to restore normality in Addisonian patients lies in an inadequate dosage of cortisone. Although small doses of 12.5 mg. with additional deoxycortone may enable the Addisonian patient to live in sodium balance, she will remain often lacking in energy, resisting infections indifferently, and remaining deeply pigmented. Since 1951 we have aimed at full physiological replacement-37.5-50 mg. of cortisone daily by mouth.
The early-morning dose being the more important, it is common practice to give the larger dose, 25 mg., at this time, for it is in the morning that the patient feels the need of cortisone more particularly, and there is evidence that in the normal man adrenocortical secretion is highest at this time. On full dosage the patient improves remarkably, and gradually loses her abnormal pigment from skin and buccal mucosa. The change from the thin pigmented state to the plump pink one has a great psychological effect on the patient quite apart from the physical well-being that goes with it.
Cortisone alone in the above dosage may be enough to maintain the patient in good general health. Although it has only one-fiftieth to one-thirtieth the salt-retaining effect of deoxycortone, this seems to be enough for many patients, but there appears to be considerable variation in individual requirements in this respect. Some patients clinically normally balanced and symptom-free are found to be in negative sodium balance (Garrod et al., 1955) when investigated more thoroughly, but in practice many do not appear to need a salt-retaining substance as a routine day-to-day measure. Case 2 is of interest in this respect.
Many potent sodium-retaining substances have been discovered in the last few years, and though deoxycortone acetate may still be used in its various forms we have far more potent substances in aldosterone, 9a-fluorohydrocortisone, and 2-methyl-9a-fluorohydrocortisone. None of these substances are as yet generally available for therapy, but we have used 9a-fluorohydrocortisone extensively and are impressed by its usefulness: Our practice is to start the Addisonian patient on 37.5-50 mg. of cortisone acetate a day by mouth and only to add salt-retaining substances if the need becomes apparent. As with the adrenalectomized patients, pamphlets are given explaining the rationale of the therapy and the need for increased dosage in times of stress.
Adrenal Crisis
Adrenal crisis was once rare and almost confined to Addison's disease. In these days of more frequent adrenal surgery it is not uncommon. It may be seen in a variety of different forms (Hart, 1956) : (1) These two groups-malignant hypertension and Cushing's syndrome-have been no great problem as regards substitution therapy after the first few weeks. The same cannot be said of the cases of metastatic malignant disease, for the malignant process eventually recurs, the appetite disappears, and there is none of the day-to-day and week-to-week stability of the other two groups.
Gastro-intestinal disturbances are common; one is dealing with a patient in whom activity of underlying malignant process, salt and fluid balance, and cortisone requirements are unknown daily variables.
If episodes of cyclical vomiting occur before adrenalectomy in such patients, it is almost certain that they will also occur after this operation, and the use of a salt-retaining substance in addition to cortisone will probably be necessary from the start. Case 1 is interesting in this context.
Although metastatic involvement of the adrenal cortex was common in these metastatic patients, occurring in some 60% of cases (Cade, 1955) The discovery by Stone et al. (1956) that mecamylamine (" inversine "), a secondary amine, has pharmacological properties in many ways similar to those of the quaternary ammonium compounds, which are tertiary amines, is of interest not only in relationship to the properties of the substance itself but also because other secondary amines as yet untested may prove to be more satisfactory as ganglion-blocking drugs than any of those now available. On the basis of both animal (Ford et al., 1955; Stone et al., 1956 ) and clinical studies (Ford et al., 1955; Freis, 1955; Freis and Wilson, 1955, 1956; Moyer et al., 1955) it is evident that mecamylamine causes blockade of both sympathetic and parasympathetic ganglia. It differs from the methonium compounds, however, in being readily and completely, or almost completely, absorbed from the alimentary canal. It has also been reported (Freis and Wilson, 1955, 1956 ) that, contrary to the invariable course of events with the methonium compounds, the continued administration of mecamyl- Readings (1939) in order to maintain uniformity with observations published previously on hexamethonium, pentolinium (" ansolysen "), and chlorisondamine (" ecolid ") (Restall and Smirk, 1950; Smirk and Alstad, 1951 ; Smirk, 1953; Smirk and Hamilton, 1956) .
Over a period of from four to eight months (average 4.6) 40 patients (20 males, 20 females) have received a trial of mecamylamine. Fundal gradings were or had been grade IV (Keith, Wagener, and Barker, 1939) in five cases, grade III in nine, and grades II or I in the remainder, most of whom had other severe manifestations such as congestive cardiac failure. Twenty-five patients had had treatment with other ganglion-blocking agents previously. In the remainder treatment was instituted with mecamylamine.
Drug Toleration
Before comparing the potencies of mecamylamine and other ganglion-blocking drugs it is necessary to consider whether mecamylamine causes drug toleration. At an early stage it became evident that toleration either did not occur or was present to a comparatively minor degree following the repeated administration of mecamylamine. Indeed, if drug toleration does develop it must do so early in the course of administration of gradually increasing doses; for once a fully effective dose has been discovered there is no consistent change in the dose needed to reproduce the same fall of blood pressure. In some instances the requisite dose has increased somewhat after several weeks or months of treatment; in other instances, somewhat less frequently, the requisite dose has decreased. In Fig. 1 
